Pub. Date : 2022 May 12
PMID : 35570009
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients-Preliminary Report. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 2 | BACKGROUND: Previous reports have established that patient CYP3A5 allelic variability may be the most important genetic contributor to interindividual variation in tacrolimus exposure in renal transplant recipients. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 3 | The aim of this study was to investigate the role of the renal CYP3A5 genotype in tacrolimus concentration-to-dose ratio within 3 years posttransplant. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 4 | METHODS: A retrospective cohort study of 90 renal transplant recipients and their donors evaluated the effect of the CYP3A5 single-nucleotide polymorphism (rs776746) on tacrolimus exposure. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 5 | RESULTS: A significant effect of CYP3A5 expression on tacrolimus exposure was observed in both donors (mean +- SD: 23.8 +- 7.9 vs 32.6 +- 7.4 ng/mL/mg, respectively; P < .001) and recipients (mean +- SD: 27.1 +- 8.0 vs 32.2 +- 7.9 ng/mL/mg, respectively; P = .034) and was lower when CYP3A5 enzyme occurred. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 6 | RESULTS: A significant effect of CYP3A5 expression on tacrolimus exposure was observed in both donors (mean +- SD: 23.8 +- 7.9 vs 32.6 +- 7.4 ng/mL/mg, respectively; P < .001) and recipients (mean +- SD: 27.1 +- 8.0 vs 32.2 +- 7.9 ng/mL/mg, respectively; P = .034) and was lower when CYP3A5 enzyme occurred. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 7 | Thus, new groups were formed: the group in which at least 1 of the pairs, donor or recipient, had a CYP3A5 expressing allele (n = 23) had lower exposure to tacrolimus compared with nonexpressors (n = 67; mean +- SD: 26.2 +- 7.6 vs 33.2 +- 7.4 ng/mL/mg, respectively; P < .001). | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 8 | Nonexpressors receiving kidneys with the CYP3A5*1 allele may benefit from higher tacrolimus doses to hasten achievement of target drug concentrations. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |